Skip to main content
SpringerLink
Log in

Pharmacotherapy for Hyperactivity in Children with Autism and Other Pervasive Developmental Disorders

  • Published:
Journal of Autism and Developmental Disorders Aims and scope Submit manuscript

Abstract

We reviewed pharmacological treatments used in children with autism and PDD-NOS who present with hyperactive symptoms. Some 41 studies were identified from the following drug categories: antipsychotics (n = 13), serotonin reuptake inhibitors (n = 3), antianxiety drugs (n = 4), psychostimulants (n = 10), alpha adrenergic agonists (n = 2), opiate blockers (n = 7), and other drugs (n = 2). Empirical evidence for significant reductions in hyperactive symptoms was strongest for the antipsychotics, psychostimulants, and naltrexone. Most studies have focused on the reduction of overactivity, and more emphasis needs to be placed on distractibility and attentional variables. A theoretical model was proposed in which participants' attentional performance may be used to predict clinical response to psychostimulants. More carefully controlled and comprehensive studies of hyperactivity are badly needed in these children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Aman, M. G. (1982). Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. Journal of Autism and Developmental Disorders, 12, 385–398.

    Google Scholar 

  • Aman, M. G. (1996). Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities, 8, 347–365.

    Google Scholar 

  • Aman, M. G., Van Bourgondien,, M. E., Wolford, P. C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672–1681.

    PubMed  Google Scholar 

  • American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.

    Google Scholar 

  • Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195–1202.

    PubMed  Google Scholar 

  • Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Development Disorders, 19, 227–239.

    Google Scholar 

  • Barron, J. L., & Sandman, C. A. (1985). Paradoxical excitement to sedative-hypnotic drugs in mentally retarded clients. American Journal of Mental Deficiency, 90, 124–129.

    PubMed  Google Scholar 

  • Birmaher, B., Quintana, H., & Greenhill, L. L. (1988). Methylphenidate treatment of hyperactive autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 248–251.

    PubMed  Google Scholar 

  • Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640–655.

    PubMed  Google Scholar 

  • Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.

    PubMed  Google Scholar 

  • Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koh, C. (1972). Response to tri-iodothyronine and dextroamphetamine: A study of preschool schizophrenic children. Journal of Autism and Childhood Schizophrenia, 2, 343–358.

    PubMed  Google Scholar 

  • Campbell, M., Overall, J. E., Small, A. M., Sokol, M. S., Spencer, E. K., Adams, P., Foltz, R. L., Monti, K. M., Perry, R., Nobler, M., & Roberts, E. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 200–206.

    PubMed  Google Scholar 

  • Campbell, M., Small, A. M., Collins, P. J., Friedman, E., David, R., & Genieser, N. (1976). Levodopa and levoamphetamine: A crossover study in young schizophrenic children. Current Therapeutic Research, 19, 70–86.

    PubMed  Google Scholar 

  • Fatemi, S. H., Realmuto, G. M., Khan, L., & Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: A longitudinal open trial. Journal of Autism and Developmental Disorders, 28, 303–307.

    Google Scholar 

  • Fisman, S., & Steele, M. (1996). Use of risperidone in pervasive developmental disorders: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 177–190.

    PubMed  Google Scholar 

  • Frankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1991). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77–82.

    Google Scholar 

  • Geller, B., Guttmacher, L. B., & Bleeg, M. (1981). Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. American Journal of Psychiatry, 138, 388–389.

    PubMed  Google Scholar 

  • Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363–366.

    PubMed  Google Scholar 

  • Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447.

    PubMed  Google Scholar 

  • Handen, B. L., Johnson, C. R., & Lubetsky, M. (in press). Efficacy of methylphenidate among children with autism and symptoms of ADHD. Journal of Autism and Developmental Disorders.

  • Horrigan, J. P., & Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders, 27, 313–323.

    PubMed  Google Scholar 

  • Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322–327.

    PubMed  Google Scholar 

  • Joshi, P. T., Capozzoli, J. A., & Coyle, J. T. (1988). Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder. American Journal of Psychiatry, 145, 335–338.

    PubMed  Google Scholar 

  • King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A.W., MacMahon, W., Cantwell, E., Davanzo, P. A., Dourish, C., Dykens, E. M., Jaselskis, C. A. Leventhal, B. L., Lubetsky, M. J., Myers, S. M., Ozonoff, S., Shah, B. G., Leavitt, J., Shape, M., Steele, E. W., Williamson, K., & Cook, Jr., E. H. (1999, October). A double blind placebo controlled study of amantadine hydrochloride in treatment of children with autistic disorder. Poster presentation given at the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Chicago, IL.

  • Kolmen, B. K., Feldman, H., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: A double bind placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 223–231.

    PubMed  Google Scholar 

  • Kolmen, B. K., Feldman, H., Handen, B. L., & Janosky, J. E. (1997). Naltrexone in young autistic children: Replication study and learning measures. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1570–1578.

    PubMed  Google Scholar 

  • Locascio, J. J., Malone, R. P., Small, A. M., Kafantaris, V., Ernst, M., Lynch, N. S., Overall, J. E., & Campbell, M. (1991). Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacology Bulletin, 27, 119–126.

    PubMed  Google Scholar 

  • Lovaas, O. I., Koegel, R. L., & Schreibman, L. (1979). Stimulus overselectivity in autism: A review of research. Psychological Bulletin, 86, 1236–1254.

    PubMed  Google Scholar 

  • Lyon, M., & Robbins, T. (1975). The action of central nervous system stimulant drugs: A general theory concerning amphetamine effects. In W. B. Essman & L. Valzelli (Eds.), Current developments in psychopharmacology (Vol. 2). New York: Spectrum.

    Google Scholar 

  • Malek-Ahmadi, P., & Simonds, J. F. (1998). Olanzapine for autistic disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 902.

    PubMed  Google Scholar 

  • Marrosu, F., Marrosu, G., Rachel, M. G., & Biggio, G. (1987). Paradoxical reactions elicited by diazepam in children with classic autism. Functional Neurology, 3, 355–361.

    Google Scholar 

  • McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685–693.

    PubMed  Google Scholar 

  • McCormick, L. H. (1997). Treatment with buspirone in a patient with autism. Archives of Family Medicine, 6, 368–370.

    PubMed  Google Scholar 

  • Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. American Academy of Child and Adolescent Psychiatry, 37, 372–376.

    Google Scholar 

  • Overall, J. E., & Campbell, M. (1988). Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical Psychology, 44, 708–716.

    PubMed  Google Scholar 

  • Perry, R., Pataki, C., Munoz-Silva, D. M., Armenteros, J., & Silva, R. R. (1997). Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology, 7, 167–179.

    PubMed  Google Scholar 

  • Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19, 37–44.

    PubMed  Google Scholar 

  • Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283–294.

    PubMed  Google Scholar 

  • Rapoport, J. L., Buchsbaum, M. S., Weingartner, H., Zahn, T. P., Ludlow, C., & Mikkelsen, E. J. (1980). Dextro-amphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933–943.

    PubMed  Google Scholar 

  • Realmuto, G. M., August, G. J., & Garfinkel, B. D. (1989). Clinical effect of buspirone in autistic children. Journal of Clinical Psychopharmacology, 9, 122–125.

    PubMed  Google Scholar 

  • Robbins, T. W., & Sahakian, B. J. (1979). “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology, 18, 931–950.

    PubMed  Google Scholar 

  • Sandman, C. A., & Barron, J. L. (1992). Paradoxical response to sedative/ hypnotics in patients with self-injurious behavior and stereotypy. Journal of Developmental and Physical Disabilities, 4, 307–316.

    Google Scholar 

  • Schmidt, K. (1982). The effect of stimulant medication in childhood-onset pervasive developmental disorder: A case report. Journal of Developmental and Behavioral Pediatrics, 3, 244–246.

    PubMed  Google Scholar 

  • Sporn, A., & Pinsker, H. (1981). Use of stimulant medication in treating pervasive developmental disorder. American Journal of Psychiatry, 138, 997.

    Google Scholar 

  • Strayhorn, J. M., Rapp, N., Donina, W., & Strain, P. S. (1988). Randomized trial of methylphenidate for autistic child. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 244–247.

    PubMed  Google Scholar 

  • Vitriol, C., & Farber, B. (1981). Stimulant medication in certain childhood disorders. American Journal of Psychiatry, 138, 1517–1518.

    Google Scholar 

  • Volkmar, F., Hoder, E. L., & Cohen, D. J. (1985). Inappropriate uses of stimulant medications. Clinical Pediatrics, 24, 127–130.

    PubMed  Google Scholar 

  • Ullman, D. G. (1974). Breadth of attention and retention in mentally retarded and intellectually average children. American Journal of Mental Deficiency, 78, 640–648.

    PubMed  Google Scholar 

  • Uvebrant, P., & Bauziene, R. (1994). Intractable epilepsy in children. The efficacy of lamotrigine treatment, including nonseizure-related benefits. Neuropediatrics, 25, 284–289.

    PubMed  Google Scholar 

  • Werry, J. S., & Aman, M. G. (1984). Methylphenidate in hyperactive and enuretic children. In B. Shopsin & L. Greenhill (Eds.), The psychobiology of childhood: Profile of current issues (pp. 183–195). Jamaica, NY: Spectrum.

    Google Scholar 

  • Werry, J. S., & Aman, M. G. (1999). Anxiolytics, sedatives, and miscellaneous drugs. In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp, 433–469). New York: Plenum Medical Book.

    Google Scholar 

  • Willemsen-Swinkles, S. H. N., Buitelaar, J. K., van Berckelaer-Onnes, I. A., & van Engeland, H. (1999). Brief report: Six months continuation treatment in naltrexone-responsive children with autism: An open-label case-control design. Journal of Autism and Developmental Disorders, 29, 167–169.

    PubMed  Google Scholar 

  • Willemsen-Swinkles, S. H. N., Buitelaar, J. K., & van Engeland, H. (1996). The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study. Society of Biological Psychiatry, 39, 1023–1031.

    Google Scholar 

  • Willemsen-Swinkles, S. H. N., Buitelaar, J. K., Weijnen, F. G., & van Engeland, H. (1995). Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research, 58, 203–215.

    PubMed  Google Scholar 

  • World Health Organization. (1993). The ICD-10 classification of mental and behavioural disorders. Geneva: Author.

    Google Scholar 

  • Zeaman, D., & House, B. J. (1963). The role of attention in retardate discrimination learning. In N. R. Ellis (Ed.), Handbook of mental deficiency. New York: McGraw-Hill.

    Google Scholar 

  • Zuddas, A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry, 153, 738.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University, Columbus, Ohio

    Michael G. Aman & Kristen S. Langworthy

Authors
  1. Michael G. Aman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristen S. Langworthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aman, M.G., Langworthy, K.S. Pharmacotherapy for Hyperactivity in Children with Autism and Other Pervasive Developmental Disorders. J Autism Dev Disord 30, 451–459 (2000). https://doi.org/10.1023/A:1005559725475

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005559725475

Search

Navigation